Archive for May, 2010

We are launching our Report Store

Posted by lifetech on May 25th, 2010

Since 2003, LifeTech has conducted in-depth analyses of hundreds of biotech & pharma products, devices and diagnostics. It is an amazing knowledge base that we are now opening to the outside world. We dig deep and provide opinions that are actionable and solid. We are doctors and scientists with unique experiences and perspectives. We know FDA well, we know many people who used to work there, and we collaborate with them on our projects. We ask critical questions around the design of clinical trials and interrogate the validity of study results. We know how clinicians make decisions to adopt new technologies. We understand reimbursement policy decisions that drive purchasing decisions, and we have a vision for the changing face of healthcare. Our reports are for those truly interested in an expert, independent opinion regarding a product’s chances for success measured on many fronts: clinical trial outcomes;  FDA approval and success in the marketplace. Interested to see the quality of our work? We welcome you to explore. Alternatively, please email us. We look forward to sharing our approach with you!

Vertex is seeking to expand the frontiers of cystic fibrosis treatment!

Posted by admin on May 5th, 2010

 We just published our report on Vertex’s experimental drugs for CF:  VX-770 is generating a lot of buzz among experts and patients. We examined what this excitement is all about and what it could mean for patients and – of course – for Vertex. In a nutshell, VX-770 is a CFTR modulator, a new treatment approach that attempts to fix the genetic defect that causes cystic fibrosis. If successful, it could theoretically alter the natural history of the disease. This would be huge for patients. The current phase III trial is focusing on patients with the G551D mutation, which is not very common. The million (or billion) dollar question for Vertex is not so much related to VX-770’s effects in the G551D mutation, but rather whether it might work on the ubiquitous F508del mutation. This mutation affects up to 90% of the patients. Our report details the history of VX-770 and its prospects for success in phase III and beyond … a fascinating story worth following closely.